James Crowe
Faculty Member
Last active: 3/31/2020

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.

Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Crowe JE, Zeitlin L, Geisbert TW
Sci Transl Med. 2017 9 (384)

PMID: 28381540 · PMCID: PMC5719873 · DOI:10.1126/scitranslmed.aai8711

As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.

Copyright © 2017, American Association for the Advancement of Science.

MeSH Terms (12)

Animals Antibodies, Monoclonal Cross Protection Filoviridae Filoviridae Infections Guinea Pigs Humans Macaca fascicularis Macaca mulatta Marburgvirus Marburg Virus Disease Pilot Projects

Connections (1)

This publication is referenced by other Labnodes entities: